CF PharmTech (02652) spent HKD 52,700 on February 9 to repurchase 1,500 shares.

18:16 09/02/2026

Changfeng Pharmaceutical (02652) announced that the company repurchased 1500 shares on February 9, 2026, at a cost of 52,700 Hong Kong dollars, with a repurchase price per share range of 35.08-35.12 Hong Kong dollars.

CF PHARMTECH (02652) announced that the company repurchased 1500 shares on February 9, 2026 at a cost of 52,700 Hong Kong dollars. The repurchase price per share was between 35.08-35.12 Hong Kong dollars.

CDB INT'L INV (01062) issued a profit warning, expecting the company's owner's loss in 2025 to decrease to no more than approximately HK$64.8 million.

CHINARES PHARMA (03320) is potentially selling about 17.87% equity in Tianmai Biotechnology.

Jouder Precision Industry (Kunshan) Co., Ltd. (300549.SZ) shareholder UCM plans to reduce its shareholding by no more than 3%.

CDB INT'L INV (01062) issued a profit warning, expecting the company's owner's loss in 2025 to decrease to no more than approximately HK$64.8 million.

CHINARES PHARMA (03320) is potentially selling about 17.87% equity in Tianmai Biotechnology.

Jouder Precision Industry (Kunshan) Co., Ltd. (300549.SZ) shareholder UCM plans to reduce its shareholding by no more than 3%.